BONE AND RENAL OUTCOMES IN VIROLOGICALLY CONTROLLED ADOLESCENTS SWITCHING TO TDF
Tenofovir disoproxil fumarate (TDF) is included in first line regimens for adolescents living with HIV (ALWH), however associated bone and renal toxicity are concerning. TDF used in combination for treatment-naïve ALWH or those with treatment failure is associated with decreased bone mass. Whether switching to TDF causes decreased bone accrual or bone loss in virologically…